Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Patient Education
Share your love
Eyenovia and SGN Nanopharma to Develop Dry Eye Treatment
Eyenovia and SGN Nanopharma have announced a new collaboration to develop a treatment for chronic dry eye disease. Eyenovia, known for its two FDA-approved products and a late-stage asset in pediatric progressive myopia, will work with SGN Nanopharma to develop…
Novaliq’s Vevizye® Receives Positive CHMP Opinion for DED
Novaliq announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has given a positive opinion recommending the granting of a marketing authorization for Vevizye® in the European Union. This therapy is designed to treat moderate…
Elon Musk’s Blindsight Implant Faces Skepticism from Researchers
Elon Musk recently announced on X that Blindsight, a cortical implant to restore vision, would have low resolution at first “but may ultimately exceed normal human vision.” Skepticism from University of Washington Research New research from the University of Washington…
Dr. Allen C. Ho Appointed Chairman of Alcon Research Institute
Alcon announced that Allen C. Ho, MD, will join the Alcon Research Institute’s (ARI) Executive Committee as chairman in October. The executive committee has overseen ARI’s mission to expand the frontiers of vision sciences globally since its founding in 1981,…
Researchers Discover Potential Therapeutic Target for Dry AMD
Researchers from the National Institutes of Health (NIH) have made a significant breakthrough in understanding the dysfunction associated with waste removal in the retina, offering new insights into dry age-related macular degeneration (AMD). A recent report from NIH and Johns…
GLP1RAs Linked to Higher DR Progression Risk vs. SGLT2is
A new study published online July 19 in Diabetes, Obesity and Metabolism has highlighted significant concerns regarding the treatment of diabetic retinopathy (DR) in patients with diabetes. The research indicates that treatment with glucagon-like peptide 1 receptor agonists (GLP1RAs) is…
Link Between Proteins in Tears and Pain After Eye Surgery
In a study published in the Journal of Proteome Research, researchers from Oregon Health & Science University (OHSU) have identified a connection between specific proteins found in patients’ tears and persistent pain experienced months after eye surgery. This discovery could…
New Insights on Retinoblastoma Treatment
Recent research presented at the Society of NeuroInterventional Surgery’s (SNIS) 21st Annual Meeting underscores significant improvements in treating retinoblastoma, a rare eye cancer affecting young children. The study reveals that advancements in treatment over the past 15 years have notably…
Nicox Concludes U.S. Recruitment for Phase 3 NCX 470 Trial
Nicox announced the recruitment and randomization of the final patient in the United States for its Denali Phase 3 trial of NCX 470. This milestone marks a significant step in evaluating the safety and efficacy of NCX 470 for patients…
Spryte’s nOCT Tech Gets FDA Breakthrough Device Designation
Spryte Medical announced that its Neuro Optical Coherence Tomography (nOCT) technology has been awarded Breakthrough Device Designation by the FDA. This designation highlights the potential of nOCT to revolutionize neurointervention and cerebrovascular treatment. FDA Breakthrough Device Designation The FDA’s Breakthrough…